A Phase 2 interventional study of Capecitabine [Xeloda] and Oxaliplatin in Gastric Cancer, sponsored by Hoffmann-La Roche. Completed at 30 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-01.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 100 studies testing capecitabine in Stomach Neoplasms — 9 open to participants now, 13 under way, 5 of them phase 3. Capecitabine · Stomach Neoplasms.
Among the 100 studies testing capecitabine in Stomach Neoplasms, this one is the 68th largest by enrollment of the 97 interventional ones that give a count, is one of 7 that started in 2010, is one of 58 in phase 2, and was the 49th registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.
Browse Stomach Neoplasms studies →9 of the 100 studies testing capecitabine in Stomach Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Jinbo Yue · Sites in China
Ages 18–75
AstraZeneca · Sites in United States, Canada, China and 8 more countries
Ages 18+
Henry Ford Health System · Sites in United States
Ages 18+
RemeGen Co., Ltd. · Sites in China
Ages 18+
Hallym University Medical Center · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
100 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 65 · Phase 3 19 · Phase 4 2
First in 1999; this study’s year is marked. 7 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 66 across 2,500 interventional studies indexed under Stomach Neoplasms.
Median enrollment 50 across the 97 interventional studies. Of the 66 that completed or were terminated, 21 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 100 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
29 studies in Stomach Neoplasms by Hoffmann-La Roche: none open now, 2 under way, none of them phase 3. Of 27 finished, 15 (56%) have results posted.
Among the 29 studies in Stomach Neoplasms by Hoffmann-La Roche, this one is the 18th largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2010, is one of 11 in phase 2, and was the 5th registered.
Hoffmann-La Roche’s Stomach Neoplasms studies by the year they started, since 2003.
3 of the studies testing capecitabine in Stomach Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06065371Henry Ford Health SystemSacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | 2026-12 |
| NCT06748508Fudan UniversityComparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer | 2027-07-25 |
| NCT07069712AstraZenecaA Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma | 2027-11-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 100 studies testing capecitabine in Stomach Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 29 in Stomach Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the disease free survival rate of a combination of capecitabine [Xeloda] and oxaliplatin (XELOX) with trastuzumab [Herceptin] in patients with resectable gastric cancer. The combination of Xeloda (orally, 1000 mg/m2 on day 1-14 of every cycle) and Herceptin (intravenously, 8 mg/kg loading dose, then 6 mg/kg on days 1-14 of every cycle) will be administered for three cycles prior to surgery to resect the tumor. If complete resection, R0 or microscopic residual tumor R1 is achieved, patients will continue with three cycles of XELOX and Herceptin and then for completion of 12 months treatment with Herceptin alone. Oxaliplatin will be administered intravenously at a dose of 130 mg/m2 on day 1 in every cycle. The anticipated time on study drug will be 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Capecitabine [Xeloda] · Drug: Oxaliplatin · Drug: Trastuzumab [Herceptin]
1.000 mg/m2 orally every 12 hours from day 1 to day 14 of every cycle for 6 cycles
130 mg/m2 intravenous infusion day 1 of every cycle
First dose 8 mg/kg, subsequent cycles 6 mg/kg, intravenously, day of every cycle for 15 cycles
Percentage of Participants With Disease-free Survival (DFS) at Month 18
DFS was the time elapsed from the time of surgery (for complete resection \[R0\] participants) until the date on which progression or death from any cause was documented (whichever occured first). Progression was defined as target lesions greater than (\>) 20 percent (%) increase in the sum of the longest diameter (SLD) taking as reference the smallest SLD recorded since the treatment started (nadir) and minimum 5 millimeter (mm) increase over the nadir. When the sum becomes very small, increases within the measurement error (2-3 mm) can lead to a 20% increase. Participants who did not present progression and who had not died were censored on the last date on which it was known that there was no progression (last response assessment).
Time frame: Month 18
Percentage of Participants With Pathological Complete Response (pCR)
pCR was defined as an absence of any invasive cancer cell of the primary tumor after the time of major neoadjuvant chemotherapy, with or without surgery.
Time frame: Between Days 7 and 21 of the 3rd cycle of neoadjuvant treatment, thereafter, every 9 weeks during adjuvant treatment and then after adjuvant treatment every 3 months until Month 25
Percentage of Participants With Complete Tumor Resection (R0)
R0 resection was defined as having performed a complete resection of the tumor with adequate tumor-free margins and regional lymph node extirpation.
Time frame: Between Days 7 and 21 of the 3rd cycle of neoadjuvant treatment, thereafter, every 9 weeks during adjuvant treatment and then after adjuvant treatment every 3 months until Month 25
Percentage of Participants With Objective Response
An objective response was defined as either a complete response (CR) or a partial response (PR). Using the Response Evaluation Criteria in Solid Tumors (RECIST), CR was defined as the disappearance of all target lesions and all non-target lesions, normalization of tumor marker level, and no new lesions. PR was defined as the disappearance of all target lesions and persistence of greater than or equal to (≥) 1 non-target lesions and/or the maintenance of tumor marker level above the normal limits, or, at least a 30% decrease in the sum of the longest diameter of target lesions, and no new lesions or unequivocal progression of existing non-target lesions.
Time frame: Between Days 7 and 21 of the 3rd cycle of neoadjuvant treatment, thereafter, every 9 weeks during adjuvant treatment and then after adjuvant treatment every 3 months until Month 25
| Milestone | Capecitabine+Oxaliplatin+Trastuzumab |
|---|---|
| Started | 36 |
| Completed | 22 |
| Not completed | 14 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Principal investigator decision | 1 |
| Withdrew: Death | 1 |
| Withdrew: Disease progression | 1 |
| Withdrew: Toxicity, ae/intercurrent disease | 7 |
| Withdrew: Surgical resection (r2) | 1 |
DFS was the time elapsed from the time of surgery (for complete resection \[R0\] participants) until the date on which progression or death from any cause was documented (whichever occured first). Progression was defined as target lesions greater than (\>) 20 percent (%) increase in the sum of the longest diameter (SLD) taking as reference the smallest SLD recorded since the treatment started (nadir) and minimum 5 millimeter (mm) increase over the nadir. When the sum becomes very small, increases within the measurement error (2-3 mm) can lead to a 20% increase. Participants who did not present progression and who had not died were censored on the last date on which it was known that there was no progression (last response assessment).
| percentage of participants | Capecitabine+Oxaliplatin+Trastuzumab |
|---|---|
| Percentage of Participants With Disease-free Survival (DFS) at Month 18 | 76.12 (57.72 to 87.32) |
pCR was defined as an absence of any invasive cancer cell of the primary tumor after the time of major neoadjuvant chemotherapy, with or without surgery.
| percentage of participants | Capecitabine+Oxaliplatin+Trastuzumab |
|---|---|
| Percentage of Participants With Pathological Complete Response (pCR) | 8.33 (1.75 to 22.47) |
R0 resection was defined as having performed a complete resection of the tumor with adequate tumor-free margins and regional lymph node extirpation.
| percentage of participants | Capecitabine+Oxaliplatin+Trastuzumab |
|---|---|
| Percentage of Participants With Complete Tumor Resection (R0) | 90.32 (74.25 to 97.96) |
An objective response was defined as either a complete response (CR) or a partial response (PR). Using the Response Evaluation Criteria in Solid Tumors (RECIST), CR was defined as the disappearance of all target lesions and all non-target lesions, normalization of tumor marker level, and no new lesions. PR was defined as the disappearance of all target lesions and persistence of greater than or equal to (≥) 1 non-target lesions and/or the maintenance of tumor marker level above the normal limits, or, at least a 30% decrease in the sum of the longest diameter of target lesions, and no new lesions or unequivocal progression of existing non-target lesions.
| percentage of participants | Capecitabine+Oxaliplatin+Trastuzumab |
|---|---|
| Percentage of Participants With Objective Response | 38.89 |
Collected over Before Day 1 of each cycle until Month 25. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Capecitabine+Oxaliplatin+Trastuzumab | — | 22/36 (61.1%) | 35/36 (97.2%) |
| Event | Capecitabine+Oxaliplatin+Trastuzumab |
|---|---|
| DiarrhoeaGastrointestinal disorders | 5/36 |
| Localised intra-abdominal fluid collectionGastrointestinal disorders | 2/36 |
| PneumoniaInfections and infestations | 2/36 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 2/36 |
| Cardiogenic shockCardiac disorders | 1/36 |
| DysphagiaGastrointestinal disorders | 1/36 |
| Intestinal ischaemiaGastrointestinal disorders | 1/36 |
| Intestinal obstructionGastrointestinal disorders | 1/36 |
| Oesophageal perforationGastrointestinal disorders | 1/36 |
| VomitingGastrointestinal disorders | 1/36 |
| Event | Capecitabine+Oxaliplatin+Trastuzumab |
|---|---|
| DiarrhoeaGastrointestinal disorders | 29/36 |
| AstheniaGeneral disorders | 24/36 |
| NauseaGastrointestinal disorders | 17/36 |
| VomitingGastrointestinal disorders | 15/36 |
| Decreased appetiteMetabolism and nutrition disorders | 15/36 |
| AnaemiaBlood and lymphatic system disorders | 11/36 |
| PyrexiaGeneral disorders | 10/36 |
| NeurotoxicityNervous system disorders | 10/36 |
| Abdominal painGastrointestinal disorders | 9/36 |
| Mucosal inflammationGeneral disorders | 8/36 |
Intent-to-treat (ITT) population included all enrolled participants.
| Age, Continuous(years) | Capecitabine+Oxaliplatin+Trastuzumab |
|---|---|
| Mean | 63.44 ± 10.42 |
| Sex: Female, Male(Participants) | Capecitabine+Oxaliplatin+Trastuzumab |
|---|---|
| Female | 7 |
| Male | 29 |
The record gives a start of Jul 2010, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Capecitabine · Oxaliplatin · Trastuzumab